MedWatch

Medicines Council refuses dialogue with Biogen

After the second rejection of the muscular atrophy drug Spinraza, Biogen invites the Danish Medicines Council to a dialogue meeting. The aim is to solve the apparently deadlocked conflict but the Medicines Council rejects the proposal. General Manager in Biogen does not understand the decision.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Sunstone-selskab nærmere svensk hovedbørs

Det svenske biotekselskab Cantargia fortsætter bestræbelserne mod at blive noteret på den svenske hovedbørs Nasdaq Stockholm og lever nu op til forudsætninger for dette.

Related articles